<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The compliance of patients with moderately expressed and moderately severe <z:hpo ids='HP_0000726'>dementia</z:hpo>, caused by <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), to the treatment with two different dose regimes of akatinol memantine was studied </plain></SENT>
<SENT sid="1" pm="."><plain>The study included 40 patients with AD and mixed Alzheimer-vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (AD/VD) aged from 53 to 84 years </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were stratified into 2 groups: patients of group 1 received akatinol memantine in a single dose 20 mg in the morning and patients of group 2 received the drug twice in dose 10 mg in the morning and in the afternoon </plain></SENT>
<SENT sid="3" pm="."><plain>The treatment duration was 24 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>The single dose of drug was as effective and safety as standard treatment with two doses </plain></SENT>
<SENT sid="5" pm="."><plain>Therefore, treatment with a single dose of 20 mg akatinol memantine is recommended for clinical practice </plain></SENT>
</text></document>